Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Donor-derived CD19 CAR T cells in children and young adults with relapsed CD19-positive acute leukemia after allo-HSCT
2021-003445-37Phase 2Active
- Sponsor
- Aghia Sophia Children's Hospital of Athens
- Start
- Sep 2022
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of DDCART-CD19 in acute lymphoblastic leukemia (ALL), sponsored by Aghia Sophia Children's Hospital of Athens. Primary endpoint: Complete remission within 30 days. Started Sep 2022; status: active.
02
Drugs
DDCART-CD19
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on 2021-003445-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003445-37.